News

Neugenesis has collaborated with PATH to develop an influenza vaccine production system. Under the agreement, Neugenesis would conduct proof of concept work to demonstrate the utility of the

ARYx has announced the results from phase 2/3 clinical trial, EmbraceAC, comparing anticoagulant agent tecarfarin (ATI-5923) with oral anticoagulant warfarin. In the trial, tecarfarin demonstrated efficacy essentially the

Pharmasset has nominated PSI-352938 (PSI-938) as a lead development candidate from two series of purine analogs, for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is

Access’ preclinical data has demonstrated that thiarabine shows efficacy in the prevention and treatment of rheumatoid arthritis (RA). In a well-established animal model for RA, a good restoration

EMEA has agreed to an oral explanation in support of the Cell Therapeutics’ OPAXIO Marketing Authorization Application (MAA) in September 2009. It extended the review for the Committee

GTx has initiated Phase I multiple ascending dose clinical trial evaluating GTx-758, an oral LH inhibitor for first line treatment of advanced prostate cancer. A Phase I single

Press Ganey, a health care improvement firm, is all set to open an office just outside Boston, to house its growing information technology and PatientFlow teams. The new

Pluristem has enrolled the first patient in a phase-I clinical trial of allogeneic placental-derived adherent stromal cell product, termed as PLX-PAD. PLX-PAD is to be used in patients

Lundbeck acquires Aarhus-based biotech company NeuronIcon and its technologies. At the same time, Lundbeck has signed a collaborative agreement with the University of Arhus on additional neurology research.